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Cannabinoids (CB) are defined as a class of compounds that can act on Cannabinoid receptors 1 
or 2 (CB1 or CB2) and affect human physiology. Both CB1 and CB2 receptors belong to the 
rhodopsin-like family of G-Protein Coupled Receptors (GPCRs). However, CB1 receptor is 
mainly expressed in the central nervous system, while CB2 receptor is dominantly located in the 
peripheral nervous system and immune cells. By now, scientists have discovered many CB 
ligands that have therapeutic potentials, but the limitation of non-selective ligands is the 
psychiatric side effect mediated by the activation of CB1 receptor. Although CB1 receptor is 
crucial in analgesic and anti-inflammatory effects, strategies of designing CB2 selective ligands 
are made by medicinal chemists to avoid undesirable effects in clinic. In this thesis, we 
discovered novel CB2 lead compounds with new chemical scaffolds; designed and synthesized 
four series of analogues for the structure-activity relationship (SAR) studies; tested their binding 
affinity to both CB2 and CB1 receptors; conducted in-vitro functional studies; and evaluated their 
potentials for therapeutic treatment. 
In total, four series of (E)-3-(4-Ethoxy-3-methoxyphenyl)-2-((4-methoxyphenyl) sulfonyl)-1-
phenylprop-2-en-1-one have been identified as novel cannabinoid ligands. Physicochemical 
properties were predicted and docking studies using our CB2 model was conducted. 29 
derivatives were then synthesized to conduct SAR studies. The binding affinity and selectivity 
Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-
2-en-1-one as Novel Cannabinoid Receptor 2 Ligands 
 Changrui Xing, M.S. 
University of Pittsburgh, 2016
 
 v 
for cannabinoid receptor CB1 and CB2 were then evaluated. Four compounds showed high CB2 
binding affinity (Ki of 10-60 nM) and good selectivity (CB1/CB2 of 20- to 1305 fold). Their off-
targets effects were also predicted. Overall, these sulfone derivatives can be used to develop 
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1.0  INTRODUCTION 
1.1     ENDOCANNABINOID SYSTEM AND CANNABINOID RECEPTORS 
1.1.1    ENDOCANNABINOID SYSTEM 
Cannabinoids (CB) are defined as a class of compounds that can act on CB receptors and affect 
human physiology. The active component of Cannabis sativa Δ9-Tetrahydrocannabinol (THC) is 
the very first cannabinoid isolated and structure-elucidated in 1964 [1]. However, the CB 
receptors and their binding sites are not identified until 1988 [2]. Later on, endogenous CB 
ligands such as Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) were 
recognized and people start uncovering the veils of endocannabinoids system, which is later 
proved to play a key role in a large spectrum of diseases such as inflammation, stroke, cancer 
and osteoporosis [1, 3]. 
It is now understood that endocannabinoid system is composed of two kinds of cannabinoid 
receptors, varies endogenous ligands (endocannabinoids) which target those receptors, and many 
enzymes that synthesize or degrade the endocannabinoids. By now, many endocannabinoids 
have been discovered including Arachidonoylethanolamine (AEA), 2-Arachidonoylglycerol (2-
AG), N-arachidonoyl dopamine (NADA) and N-palmitoylethanolamine (PEA) as shown in 
Figure 1.1. Among them, AEA and 2-AG have the highest binding affinity towards CB 
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receptors and are also believed to be the most abundant ones in human body. In 1992, AEA was 
synthesized and identified as the first endogenous ligand for the cannabinoid receptor which can 
inhibit the binding of radiolabeled cannabinoid probe. Additionally, it has similar function as 
THC to inhibit the electrically evoked twitch response to the mouse vas deferens in a 
concentration-dependent manner. In 1994, 2-AG was isolated from canine intestines and was 
characterized as second endocannabinoid which is demonstrated to share similar ability with 
THC as well [4, 5]. 
 
                                       
 
 
                           
 
Figure 1.1 Structures of several endocannabinoids 
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These endogenous ligands are lipid messengers that have been found not only in the brain but 
also in peripheral tissues. Rather than stored in the vesicles, they are synthesized in the 
postsynaptic cells when needed, be released from the postsynaptic cells and then act on the CB 
receptors located in the presynaptic membrane. It is believed that these messengers are crucial in 
the control of body movements [6] and the function of memories and pain perception [7, 8]. 
Moreover, they are involved in the regulations of cardiovascular, gastrointestinal, hypothalamic 
and reproductive functions too [9-11].  
 
1.1.2    GPCRs AND CANNABINOID RECEPTOR  
GPCRs are seven transmembrane receptors. Based on their sequence and function similarities, 
they can be grouped into six classes: Class A - Rhodopsin-like family; Class B - Secretin 
receptor family; Class C - Metabotropic glutamate family; Class D - Fungal mating pheromone 
receptors; Class E - Cyclic AMP receptors; Class F – Frizzled family [12, 13]. There are three 
common regions in GPCRs: extracellular region which contains three extracellular loops (EL1-
EL3) and an N’ terminal; the transmembrane region which contains seven transmembrane α-
helices; intracellular region which contains three intracellular loops (ICL1-ICL3) and a C’ 
terminal (Figure 1.2) [14]. They are activated by external ligands or mediators and are involved 
in many biological processes such as immune responses, blood pressure regulation and even 
tumor metastasis. Additionally, it is estimated that GPCRs are the targets of about 40% of all 







Figure 1.2 Systematic structure of GPCR 
Common structure of GPCR: seven transmembrane domains (TM1-TM7), three extracellular 
loops (EL1-EL3), three intracellular loops (ICL1-ICL3), extracellular N’ terminal and 








As GPCRs, cannabinoid receptors belong to Class-A (Rhodopsin-like) G-protein coupled 
receptors family, which is the most common target of FDA approved drugs as shown in Figure 
1.3 [16].  
 
  
Figure 1.3 Gene-family distribution of drugs 
The family share as a percentage of all FDA-approved drugs is displayed for the top ten families. 




At present, there are two known subtypes of cannabinoids receptors, termed Cannabinoid 
receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). CB1 receptor is a 472 amino acid 
polypeptide while CB2 receptor is a 360 amino acid polypeptide. They have 44% amino acid 
sequence homology for the whole protein and 68% in terms of the transmembrane region [17]. In 
1990, Matsuda’s group first identified CB1 receptor and isolated it from rat cerebral cortex [18]. 
One year later, Gerard and colleagues discovered CB1 receptors in human brain and testis [19]. 
In 1993, Munro and coworkers cloned CB2 receptors from human promyelocytic leukemia cells 
[17]. 
Although the two receptors have been identified, cloned and studied as potential targets for 
decades, there are still debates on where they are located and how CB ligands produce 
pharmacological effects through them [2, 20-22]. Currently, it is believed that CB1 receptor is 
most commonly expressed in the central nervous system, especially in the neuron terminals of 
the basal ganglia, cerebellum, hippocampus, neocortex, hypothalamus and limbic cortex, where 
they can enhance or prevent “depolarization-induced suppression of excitation/inhibition” 
mediated by CB ligands [23, 24]. On the other hand, CB2 receptor is believed to be expressed 
predominantly in peripheral cells and tissues derived from immune system such as spleens and 
thymus gland [25, 26], where they can modulate immune suppression, apoptosis or cell 







1.1.3    CANNABINOID RECEPTOR SIGNALING PATHWAYS 
GPCR activation: 
G proteins (guanine nucleotide-binding proteins) are a family of proteins that act as switches 
inside a cell. By attaching to the receptors on the cell membrane, they work as signal transducers 
which can connect receptors to variety of stimuli outside the cell and therefore, to intracellular 
signaling pathways.  
G proteins are made up of three subunits (α, β and γ subunits), where Gα subunit is bound to 
guanosine diphosphate (GDP) at basal state. Both CB1 and CB2 receptors are coupled with G 
protein and upon activation by cannabinoid agonists, the extracellular signals will cause 
conformational change of transmembrane region and thus facilitate the replacement of GDP with 
guanosine triphosphate (GTP) on Gα subunit. Consequently, Gα subunit will dissociate with Gβγ 
subunit and both of them will lead to numerous downstream signaling such as regulation of 
adenylyl cyclase, ceramide, mitogen-activated protein kinase (MAPK), intracellular Ca
2+,
 and 
ion channels. After the activation, the GTP on Gα subunit will be hydrolyzed by GTPase into 
GDP, which allow it to recombine to Gβγ subunit and start a new cycle [21, 27]. 
Regulation of adenylyl cyclase: 
There are four families of Gα subunits Gαs, Gαi/Gαo, Gαq/Gα11, and Gα12/Gα13 in which both 
CB1 and CB2 receptors are coupled with Gαi/Gαo. Gαi/Gαo family is known to inhibit the 
function of adenylyl cyclase (AC). So when activated by cannabinoid agonists, Gαi/Gαo will be 
isolated from Gβγ subunit, coupled with GTP and inhibit AC activity [28]. Down regulation of 
AC will decrease the production of cyclic adenosine monophosphate (cAMP), which is a second 
messenger that affects cellular activity by regulating the activation of protein kinase, the function 
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of ion channel or the effects of adrenaline and glucagon [29-32]. In addition, the level of AC or 
cAMP in a cell is critical in terms of characterizing a ligand’s efficacy towards CB receptors. 
The inhibition of AC by THC in neuroblastoma cells is the very first signal transduction 
response discovered by Howlett and Fleming in1980s. Also, evidence showed that agonists such 
as AEA, WIN 55,212-2 or CP 55,940 can inhibit adenylyl cyclase activity and thus decrease the 
level of cAMP in rat cerebellar membranes [33, 34], where inverse agonists or antagonists such 
as SR141716 and cannabidiol can inhibit the dissociation of Gα subunit from Gβγ subunit and 
therefore upregulate the amount of cAMP [35]. 
Regulation of MAPK: 
MAPK pathway is one of the most important pathways that regulate cell proliferation, apoptosis, 
differentiation and gene expression [36]. Initiated by the activation of tyrosine kinase-linked 
receptors, G protein Ras is then activated. This will lead to a signal cascades that activate 
serine/threonine kinase Raf, which will later on activate MAPK and regulate the phosphorylation 
of many other proteins [21]. In 1995, Bernard and colleagues found that cannabinoid can induce 
the activation of MAPK in Chinese Hamster Ovary cells (CHO cells) that express human CB1 
receptors [37]. In 1996, the same group showed that cannabinoids can also activate MAPK in 
CHO cells expressing CB2 receptors [38].  
Additionally, by using WIN55212-2 in N1E-115 neuroblastoma cells, it is suggested that there 
might be other mechanisms for the regulation of MAPK pathway by cannabinoids. It was 
demonstrated that the inhibition of cAMP accumulation and the down regulation of Protein 
Kinase A (PKA) can increase the dephosphorylation of c-Raf. Consequently the Raf kinase will 
activate mitogen-activated protein kinase kinase (MAPKK) in the p42/p44 MAPK kinase [39, 
40]. 
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Modulation of ion channels: 
Ion channels exist in the membrane of all cells. By controlling the flow of ions through the 
membrane, they are involved in many physiological processes such as the conduction across the 
synapses, the regulation of cell volume and the establishing of membrane potentials [41]. CB1 
agonists AEA, WIN 55,212-2 and CP 55,940 were demonstrated to inhibit N-type voltage 
operated calcium channels (VOCCs) and therefore decrease the Ca
+
 influx in NG 108-15 cells 
[42]. In addition, AEA was proved to inhibit Q-type Ca
+
 flow in AtT-20 pituitary tumor cells that 
expressed CB1 receptors [43]. Another experiment in rat hippocampal neurons also showed that 
AEA, WIN 55,212-2 and CP 55,940 can inhibit N-type or P/Q-type Ca
+
 current [44]. Besides 
Ca
+
 channels, there are many ion channels (such as K
+
 channels and Na
+
 channels) that have also 
been proved to be inhibited by CB ligands [45, 46].  
 
1.2    THERAPEUTICAL POTENTIAL OF CANNABINOID LIGANDS 
As discussed above, endocannabinoid system plays an important role in various physiological 
processes, and CB receptors are promising targets for a wide span of diseases. Several drugs 
targeting CB1 or CB2 receptors are already in the market and there are also quite a few in clinical 
trials. More than 30 years ago, two cannabinoid derivatives dronabinol (Marinol
®
) and nabilone 
(Cesamet
®
) were approved by FDA for the treatment of nausea and vomiting [47, 48]. In 2005, a 
combination of THC and cannabidiol was licensed in Canada as Sativex
®
 to relieve the 
neuropathic pain in adults with multiple sclerosis [49]. One year later, the only cannabinoid 
receptor inverse agonist SR141716, known as Rimonabant (Acomplia
®
) was introduced to the 
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European clinics for the treatment of obesity [50, 51]. Unfortunately, side effects including 
headache, nausea, vomiting, diarrhoea, insomnia, influenza, feelings of anxiety and depression 
were observed in patients [48]. Moreover, it will increase the incidence of depression and 
suicidality. As a result, it was withdrawn from the market in 2008. 
Although there are still challenges in developing potent and selective cannabinoids as novel 
drugs, an increasing number of ligands have shown great potentials for the treatment of multiple 
myeloma, tumor or osteoporosis etc. [52, 53].  
Cannabinoids and tumor: 
Many researchers have found relationships between endocannabinoid system and all kinds of 
cancer including prostate cancer, breast cancer and multiple myeloma. It has also been reported 
that both CB receptors and endogenous cannabinoids are upregulated in tumor tissues compared 
to non-tumor tissues [54]. In addition, there are many signaling pathways that have been 
validated in terms of the anti-tumor effect of cannabinoid ligands. Several main signaling 
cascades such as ERK pathways activation, ceramide synthesis and cAMP inhibition are shown 
in 
Figure 1.4 Figure 1.4 [55]. They will eventually ameliorate the symptom of cancer by blocking 
cell cycle arrest, reducing cell proliferation and preventing tumor progression. 
Specifically, it is reported that several breast cancer cell lines (MDA-MB231, MDA-MB231-luc, 
and MDA-MB468) overexpress CB1 and CB2 receptors. Also, in vivo tests in various mouse 
model showed that cannabinoid agonists such as JWH-133 and WIN-55,212-2 can inhibit breast 
cancer cells’ proliferation and migration [56]. In addition, another study showed that human 
ErbB2-positive breast tumors express CB2 receptors and likewise, THC and JWH-133 can 
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induce cancer cell apoptosis, reduce cancer cell proliferation, and impair tumor angiogenesis 
[57]. 
Similarly, it is reported by Sami Sarfaraz and colleagues that the expression of both CB1 and CB2 
receptors are significantly increased in human prostate cancer cells (LNCaP, DUI45, PC3, and 
CWR22RN1) than in other human prostate epithelial cells. They also mentioned that with an 
induction of apoptosis, WIN-55,212-2 (CB agonist) treatment with androgen-responsive LNCaP 
cells can lead to a dose-dependent inhibition of cell growth. Another group demonstrated that 
THC can induce apoptosis in PC-3 cells, leading to morphological and biochemical alteration 
and therefore cause cell death. Additionally, people found that AEA analogues methanandamide 
(MET), as well as JWH-015 (CB agonist) can inhibit PC-3 cell proliferation too [58-62]. 
Other evidences showed that there are also relationships between endocannabinoid system and 
blood cancer or bone cancer. So according to these data, cannabinoids could be valuable in terms 
















Figure 1.4  Important signaling pathways of anti-tumor effect of cannabinoid ligands 
Main downstream signaling cascades of CB receptor are shown in this figure. The activation of 
CB receptor will eventually affect many crucial features of cancer including 1) cell-cycle arrest; 
2) the inhibition of cell proliferation; 3) the induction of cell death; 4) the prevention of tumor 






Cannabinoids and osteoporosis: 
Osteoporosis is a disease where broken bone may happen due to the decrease of bone density. It 
is associated with the imbalance between bone resorption and bone formation in the bone 
remodeling process. In this process, osteoclast cells will first be activated. They can resorb bones 
(remove old bones) and create bone cavities. Then, osteoblast cells will be activated, which can 
lead to bone formation. However in osteoporosis, more bone resorption occurs and as a result, it 
can cause bone loss. It is first reported in 2011 that human osteoclast cells express both CB1 and 
CB2 receptors, which affect osteoclast differentiation in vitro [63]. Also, two endocannabinoids 
AEA and 2-AG were found not only in the trabecular compartment of skeleton, but also in both 
osteoclast and osteoblast cells. In addition, there are a number of studies including our lab 
indicated that synthetic cannabinoid ligands such as SR141716 , AM251, AM630, CP55 940, 
JWH133 and HU308 can influence bone disease by changing bone cells’ activity and 
differentiation [63-68]. The underlying mechanism is quite complex and is concluded in Figure 
1.5 [64]. It is currently known that both CB agonists and CB inverse agonists can benefit the 
formation of bones due to their effects including increase the number of osteoblast cells, 
decrease the number of osteoclast cells or reduce the activity of osteoclast cells [63, 65, 69-72]. 
Considering the limitations of current therapies such as increasing the risk of getting cancer 
(Calcitonin) or decreasing the osteoblast cells’ function in long term uses (bisphosphonates) [73], 
it is essential to develop a better understanding of the bone remodeling process, as well as 
explore new chemical entities that have synergistic effects in terms of the regulation of both 





Figure 1.5   Regulation of bone cell activities by the CB ligands 
Cannabinoid receptor agonists can simultaneously inhibit and stimulate osteoclast formation and 
bone resorption by targeting directly on mature osteoclasts and their precursors. They can also 
stimulate osteoblast proliferation and function by targeting on the CB receptor expressed in the 
pre-osteoblasts cells. In addition, they regulate the function of osteoblast indirectly by inhibiting 
the accumulation of the Noradrenaline (NA), an inhibitor of osteoblast. Mature osteoblasts can 
produce endocannabinoids (AEA and 2-AG) and receptor activator of nuclear factor kappa-B 
ligand (RANKL), which will stimulates osteoclast formation too (The figure was adapted from 
[64]).  
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1.3    CANNABINOID RECEPTOR LIGANDS AND THEIR RECENT DEVELOPMENT 
By now, scientists have discovered many CB ligands that have therapeutic potentials, but the 
limitation of non-selective ligands is the psychiatric side effect mediated by the activation of CB1 
receptor [74]. Although CB1 receptor is crucial in analgesic and anti-inflammatory effects, 
strategies of designing CB2 selective ligands or peripheral restricted CB1 ligands are made by 
medicinal chemists to avoid undesirable effects in clinic. 
In the past decade, over 400 CB2 chemical patents, 1500 new chemical ligands have been 
developed and many of them went into clinical trials or into the market. However recently, 
legalization of cannabis in many states aroused many discussions and debates. Alaska, Colorado, 
Oregon, Washington and Washington, D.C. have legalized cannabis use for adults, and 23 states 
have legalized cannabis for non-FDA-approved medicinal uses under state law 
(https://www.whitehouse.gov/ondcp/state-laws-related-to-marijuana). Drug abuse become an 
important issue and the development of novel cannabinoid ligands with potent activity and less 
addictive effect becomes urgent.  
Although the study of cannabinoid lasted for decades, there are still many novel CB ligands or 
novel indications of classic molecules in the past year. Table 1.1 shows various cannabinoid 
ligands with novel chemical scaffolds or CB ligands with novel indications. Figure 1.6 indicates 
detailed structures of these ligands. 
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Table 1.1  Recent development of cannabinoid ligands  
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2.0  METHODS AND MATERIALS 
2.1    COMPUTER MODELING  
All molecular docking studies, pharmacophore modeling, and virtual screening procedures were 
performed using SYBYL X 1.3 (Tripos, Inc.). Molecular docking studies were performed using the 
Surflex-Dock GemXTM module in the SYBYL software. The docking interactions were analyzed 
based on the FlexX-Pharm Docking/CScore [82]. Our CB2 homology model was utilized for the 
docking and virtual screening procedures. Refined figures and contours were obtained using PyMol 
1.7 (Schrödinger®, LCC) platform [83]. Physicochemical properties were predicted using 
ChemBioDraw Ultra 14.0.Ink.                                                                                                                                           
2.2    CHEMISTRY 
All reagents were purchased from commercial suppliers and used without further purification. 
Analytical thin-layer chromatography (TLC) was performed on SiO2 plates 200 μm on EMD 
Millipore Precoated Aluminum-Backed TLC Sheets. Visualization was accomplished by ultra-
violet (UV) irradiation at 254 nm. The purification experiments were conducted using Flash 
chromatography (Biotage, Isolera Inc.). Flash column chromatography was performed using the 
Biotage Isolera flash purification system with SiO2 60 89 (particle size 0.040−0.055 mm, 
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230−400 mesh). Proton and carbon NMR were determined on Bruker 400 MHz or Bruker 600 
MHz NMR spectrometer. Chemical shifts are reported as delta (δ) values in parts per million 
(ppm) as referenced to residual solvent. 
1
H-NMR spectra are reported as follows: chemical shift, 
number of protons, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet), and coupling 
constant. Chemical shifts are reported relative to that of tetramethylsilane at 0.00 ppm.  
2.3    BIOLOGICAL EVALUATION 
2.3.1    RADIO-LIGAND COMPETITION BINDING ASSAY 
The competitive radio-ligand binding assays for CB1 and CB2 receptors were performed as 
described previously using a Perkin Elmer 96-well Top Counter to determine the cannabinoid 
receptor binding affinity (Ki) for CB1 or CB2 ligands by displacing [
3
H]-CP 55,940. [84]. Briefly, 
the compounds to be tested are diluted in binding buffer (50 mM Tris-HCl (pH 7.4), 5 mM 
MgCl2, 2.5 mM EGTA, and 0.1% (w/v) fatty acid free BSA), supplemented with 10% dimethyl 
sulfoxide and 0.4% methylcellulose. Each assay plate well contains a total of 200 μL of reaction 
mixture comprising 5 μg of CB1 (or CB2) membrane protein, labeled [
3
H]-CP 55,940 at a final 
concentration of 3 nM, and the unlabeled ligand at its varying dilutions. Plates were incubated at 
30 °C for 1 h with gentle shaking. The reaction was terminated by rapid filtration through 
Unifilter GF/B filter plates using a UniFilter cell harvester (PerkinElmer). After the plate was 
allowed to dry overnight, 30 μL MicroScint-0 cocktail (PerkinElmer) was added to each well and 
the radioactivity was counted by using a PerkinElmer TopCount. All assays were performed in 
triplicate and data points represented as mean ± S.E.M. The Ki was calculated by using nonlinear 
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regression analysis (Prism 5, GraphPad) utilizing the Cheng-Prusoff equation: Ki = IC50 / 1 + 
([L]/Kd), with the Kd values determined from saturation binding experiments. 
 
2.3.2    cAMP FUNCTIONAL ASSAY 
Cellular cAMP levels were measured according to reported method with modifications using 
LANCE cAMP 384 kits (PerkinElmer). The assay is based on competition between a europium-
labeled cAMP trace complex and total cAMP for binding sites on cAMP-specific antibodies 
labeled with a fluorescent dye. CB2 receptor wild type (WT) transfected CHO cells were seeded 
in 384- well white ProxiPlates with a density of 2000 cells per well in 5 µL of RPMI-1640 
medium containing 1% dialyzed FBS, 25 mM HEPES, 100 μg/mL penicillin, 100 U/mL 
streptomycin, and 200 μg/mL of G-418. After culture overnight, 2.5 µL of cAMP antibody and 
RO20-1724 (final concentration, 50 μM) in stimulation buffer (DPBS 1x, containing 0.1% BSA) 
was added to each well, followed by addition of either 2.5 μL of compound or forskolin (final 5 
μM) for an agonist-inhibited adenylate cyclase (AC) activity assay. After incubation at room 
temperature for 45 min, 10 µL of detection reagent was added into each well. The plate was then 
incubated for 1 h at room temperature and measured in a Synergy H1 hybrid reader (BioTek) 
with excitation at 340 nm and emission at 665 nm. Each cAMP determination was made via at 
least two independent experiments, each in triplicate. EC50 values were determined by nonlinear 
regression, dose−response curves (GraphPad Prism 5) [25, 85]. 
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3.0  RESULTS AND DISCUSSION 
3.1   LEAD DISCOVERY 
In-silico virtual screening was used to develop novel, potent and selective CB2 ligands. The 
strategy led to the discovery of a novel CB2 scaffold (NCI374672) shown in Figure 3.1. In order 
to confirm that our compound worth further optimization, its physicochemical properties was 
predicted, docking studies as well as biological evaluations were also conducted. 
 
 
Figure 3.1   Chemical structure of lead compound. 
The lead compound NCI374672 exhibited a novel chemical structure containing β-keto sulfones 





First of all, we calculated its properties using ChemBioDraw. It shows good physicochemical 
properties with molecular weight (MW) equals to 452.52, LogP equals to 3.92 and total polar 
surface area (tPSA) equals to 78.9. In addition, we used Qikprop, a module in Schrodinger 
software, to predict its drug-like properties and found that it meets all criteria.  
Molecular docking using our CB2 homology model [83] indicated the detailed interaction 
between lead compound and CB2 receptor (Figure 3.2). Results showed that lead compound 
formed strong hydrogen bonds with Thr114 (~1.8 Å) and Ser285 (~1.6 Å). Also, it has a strong 
π-π interaction with Phe281 (~3.4 Å). All these results were consistent with previous studies [83, 
86].  
    
Figure 3.2  The detailed binding pose of lead compound at CB2 receptor 
Additionally, to validate its binding affinity and selectivity towards CB2 receptor, radio-ligands 
competition binding assay was conducted. Competition binding assay was conducted on 
membrane protein harvested from CHO cells expressing CB1 or CB2 receptors. Competitive 
displacement of the [
3
H]-CP 55,940 was obtained by using an increased amount of cold ligands. 
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The lead compound showed relatively high binding activity against CB2 receptor and moderate 
selectivity over CB1 receptor (CB2 Ki = 105 nM, CB1 Ki = 836 nM, Selectivity index > 8) 
(Figure 3.3).  
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Figure 3.3     Competition binding assay for the lead compound. 
Competition binding experiments were performed on membrane proteins harvested from CHO 
cells stably expressing CB1 or CB2 receptors. Competitive displacement of the [
3
H]-CP 55,940 
was obtained by using an increased amount of cold ligands. 
 
CB2 functional activity of the lead compound was investigated by using a cell-based LANCE 
cAMP assay, which is a useful method to distinguish between agonists, inverse agonists, and 
neutral antagonists. A cellular bioassay was carried out to measure the functional activities of the 
CB2-selective compounds as described above in the method part. As shown in Figure 3.4, 
increasing concentrations of lead compound cause the reduction of the signal with an ED50 of 7.7 
µM, which indicates that the lead compound acts as a CB2 inverse agonist. 
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Figure 3.4 LANCE cAMP signal of the lead compound 
Stably transfected CHO cells expressing hCB2 receptors were used in LANCE cAMP assay. 
Assay was performed in triplicate. Data represented as mean ±SEM  
3.2   STRATEGIES FOR NEW COMPOUNDS DESIGN 
The ultimate goal of lead optimization is to develop potent and selective CB2 ligands with better 
pharmacological and physiological properties. Based on previous docking study of lead 
compound, different strategies were used to conduct SAR studies (Figure 3.5): 
1) As shown in Figure 3.2, ring C and oxygen in sulfone group show strong interactions with 
key residues (Phe281 and Ser285) of CB2 receptor. So we retained the β-keto sulfone and 
benzene ring C while introduced different functional groups (such as -F, -CH3 etc) on ring A and 
ring B;  
2) Ring A in lead compound did not show strong interactions with certain residues so we 
replaced ring A with different aromatic systems as well as linear chains to see if p-methoxyl 
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benzene ring is essential. Moreover, we can have a concept of whether three aromatic ring 
systems is essential for CB2 affinity;  
3) We also used functional groups such as -N (CH3CH2)2 in our modifications, based on our 
previous study which can not only increase selective CB2 binding affinity, but also improve 
compound solubility [25, 87]. 
 
 
                                 
                            Figure 3.5  Strategies for lead modifications 
 
After designing four series of compounds, we predicted their physicochemical properties and 
then conducted molecular docking for all the compounds that we designed. Table 3.1 shows 29 
compounds we selected (structure will be shown in SAR study part) which have a docking score 
higher than lead compound (higher than 6.02). Notably, most of them have a slightly lower or 
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similar ClogP compared to lead compound, which indicate a better or similar solubility. Figure 
3.6 shows the detailed interactions of one of the best scored compounds (compound 6d) we 
designed. Similarly, it forms strong hydrogen bonds with Thr114 (~2.1 Å) and Ser285 (~1.6 Å). 
The strong π-π interaction with Phe281 (~3.6 Å) also exists.  In addition it has relatively strong 
hydrophobic interactions with key residue Trp194 too. At the same time, it indicates that the 
replacement of aromatic ring A with linear chain did not harm the binding affinity. 
All these results suggest the potential of our lead compound and newly designed compounds. So 
we synthesized these compounds to further study their SAR. 
 
Figure 3.6  The detailed binding pose of compound 6d at CB2 receptor. 
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      Table 3.1  Calculated properties and docking score of lead and designed compounds 
 
Compound 
Calculated Properties Docking 
Score MW ClogP LogS tPSA 
Lead 452 4.50 -6.39 78.9 6.02 
5a 378 3.83 -6.17 60.4 7.73 
6a 408 3.70 -6.24 69.7 8.26 
7a 396 3.99 -6.41 60.4 7.87 
8a 457 4.66 -6.99 60.4 7.49 
9a 446 4.75 -7.13 60.4 8.32 
10a 434 5.53 -7.61 60.4 8.33 
11a 449 4.79 -7.26 63.7 8.67 
12a 358 3.89 -5.76 60.4 7.82 
13a 372 4.31 -6.18 60.4 8.15 
5b 348 3.96 -6.13 51.2 6.70 
6b 362 4.44 -6.49 51.2 6.76 
7b 419 4.92 -7.21 54.4 7.62 
5c 354 4.07 -5.56 51.2 6.03 
6c 368 4.56 -5.92 51.2 6.89 
7c 372 4.23 -5.77 51.2 6.26 
8c 433 4.90 -6.37 51.2 6.59 
9c 422 4.99 -6.49 51.2 6.89 
10c 410 5.78 -7.00 51.2 6.88 
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11c 425 5.03 -6.64 54.4 8.22 
12c 334 4.13 -5.14 51.2 6.69 
13c 348 4.55 -5.56 51.2 8.14 
5d 328 3.19 -5.43 51.2 7.59 
6d 358 4.09 -5.46 60.4 8.00 
7d 342 3.67 -5.79 51.2 7.80 
8d 346 3.34 -5.64 51.2 7.61 
9d 407 4.02 -6.24 51.2 7.73 
10d 384 4.89 -6.86 51.2 7.62 
11d 399 4.15 -6.50 54.4 8.14 















3.3    CHEMICAL SYNTHESIS 
The general synthesis route of target compounds was shown in Scheme 1 including three steps. 
Starting from four different sulfonyl chlorides (2), appropriate sodium sulfinates (3) were 
obtained according to the reaction with sodium sulfite and sodium bicarbonate under reflux 
condition. Corresponding β-keto sulfones (4) were then obtained via alkylation reaction with 
bromo-methyl ketones at 100 °C. Knoevenagel condensations using a variety of aldehydes with 
piperdine, acetic acid and toluene were then conducted at 120 °C to get four series of different 
sulfone derivatives (5a-13a, 5b-7b, 5c-13c, 5d-12d, [88, 89]). The final compounds were 
purified by flash chromatography and all the purity is higher than 95%. Their chemical structures 





              
Scheme 1: General synthesis route for sulfone derivatives.   
Reagent and conditions: (a)  Na2SO3 (1.7 equiv), NaHCO3 (1.7 equiv), H2O, 100 
o
C, 24h; (b) 2-
bromo-1-phenylethan-1-one (0.9 equiv), EtOH, H2O, 100 
o
C, 24h; (c) R
1
-CHO (1.1 equiv), 







3.4   STRUCTURE ACTIVITY RELATIONSHIP ANALYSIS 
In the first cycle of SAR study, we held R group constant as p-methoxphenyl (Table 3.2). The 
removal of methoxyl group on ring A resulted in the decrease of CB2 binding affinity 
(Compound 5a vs.6a). Additionally, the replacements of methoxyl group on benzene rings to 
halogens or trifluoromethyl group also reduced the binding activity (Compound 6a vs. 7a, 8a, 
9a). Interestingly, replacements of tertiary butyl group or diethyl amine group on the benzene 
ring dramatically increased the CB2 receptor binding affinity (Compound 10a and 11a) when 
compound 11a bearing a p-N(CH3CH2)2 group also showed greatly improved CB1/CB2 selectivity 
(Selectivity Index = 311). Furthermore, we introduced alkyl chain instead of benzene ring 
(Compound 12a and 13a), which decreased the CB2 binding activities compared to the lead 
compound. This result indicated that the aromatic ring B may be essential to keep a good 
activity. These results also confirm that electron donating groups plays an important role to 
maintain better binding affinity at R
1
 (Compound 6a-11a). Also, bulky groups are tolerated and 










Table 3.2  Radioligand competition binding affinity and physicochemical properties of 5a-
13a. 
 
Compound R1 MW CLogP Ki (CB2), nM
a Ki (CB1), nM
b SIc 
5a C6H5- 378 3.83 420.4 2650 6.3 
6a p-CH3O-C6H5- 408 3.70 134.6 2959 21.9 
7a p-F-C6H5- 396 3.99 478.0 5206 10.9 
8a p-Br-C6H5- 457 4.66 507.8 1007 1.9 
9a p-CF3-C6H5- 446 4.75 948.7 1104 1.2 
10a p-C(CH3)3-C6H5- 434 5.53 58.7 1153 19.6 
11a p-N(CH3CH2)2-C6H5- 449 4.79 43.9 13650 311.9 
12a C4H9- 358 3.89 910.1 4462 4.9 
13a C5H11- 372 4.31 300.3 1537 5.1 
Lead  - 452 4.50 105 836 7.9 
CP 55,940 - - - 0.35 NT - 
SR144528 - - - 2.05 NT - 
SR141716 - - - NT 5.6 [90] - 
 
a,b Binding affinities of compounds for CB1 and CB2 receptors were evaluated using a [
3H]-CP 55,940 
radioligand competition binding assay. c SI =selectivity index for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. 
NT: Not tested. CB2 reference compound CP 55,940, SR144528 and CB1 reference compound SR141716. 
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To continue investigate the effect of substituent on the benzene ring A, we retained the benzene 
ring and continued our SAR study (Table 3.3). Compared with compound 5a bearing a p-
methoxyl group, compound 5b exhibit little difference in terms of CB2 binding affinity, which 
indicates that methoxyl group may not be essential. Importantly, similar as compound 11a, the 
new compound 7b bearing a diethyl amine group also showed very good CB2 binding affinity as 
well as selectivity index, which is consistent with previous results [25, 87]. This result further 
confirmed the methoxyl group on ring A is not essential to keep a good CB2 binding affinity and 
selectivity. 
Table 3.3  Radioligand competition binding affinity and physicochemical properties of 5b-
7b. 
 
Compound R1 MW CLogP Ki (CB2), nM
a Ki (CB1), nM
b SIc 
5b C6H5- 348 3.96 411.7 781.5 1.8 
6b p-CH3-C6H5- 362 4.44 127.2 543.5 4.3 
7b p-N(CH3CH2)2-C6H5- 419 4.92 10.9 14220 1304.5 
Lead - 452 4.50 105 836 7.9 
CP 55,940 - - - 0.35 NT - 
SR144528 - - - 2.05 NT - 
SR141716 - - - NT 5.6[90] - 
 
a,b Binding affinities of compounds for CB1 and CB2 receptors were evaluated using a [
3H]-CP 55,940 
radioligand competition binding assay. c SI =selectivity index for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. 
NT: Not tested. CB2 reference compound CP 55,940, SR144528 and CB1 reference compound SR141716. 
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To further explore the importance of the benzene ring A, we replaced it with a heterocyclic 
thiophene ring (Table 3.4). Compounds 10c and 11c with a butyl group or a diethyl amine group 
showed the best CB2 binding affinity as expected. The introduction of a fluorine group decreased 
the CB2 binding activity while interestingly a bromine substituent enhanced the binding affinity 
(Compounds 7c and 8c). Additionally, a linear chain significantly reduced the binding affinity in 
this series than previous ones (Compound 12c and 13c). This result confirmed that the aromatic 
ring B plays important role to keep a good CB2 binding affinity. Taken together, most 
compounds in this series exhibit a little decreased affinity compared to previous two series. This 
indicates that the benzene ring A may be crucial for remaining a better CB2 binding activity.  
Then we replaced this aryl ring A with alkyl chain (butyl) to see whether our previous conclusion 
is right (Table 3.5). In this series, compounds containing a butyl group or a diethyl amine group 
also exhibited the best CB2 binding affinity (Compounds 10d and 11d). But their selectivity 
index is decreased compared to previous series. This is an interesting result and lead to a new 
hypothesis that replacing ring A with a linear chain may be a good strategy to generate new CB1 
potential compounds, which is a good direction for further studies. Similarly, a bromine 
substitution on the benzene ring (Compound 9d) showed better activity than a fluorine 
substitution (Compound 8d), which indicated that a bigger group or bulky substituent is better to 
get higher CB2 binding affinity. Moreover, if both R group and R
1
 group of the compound were 
replaced by a linear chain (Compound 12d), it completely lost its CB2 binding activity. This 
suggests the importance of at least two aromatic rings in our scaffolds. Additionally, there is a 
dramatic decrease of affinity if we compare compound 5d with 5a, 8d with 7a and 12d with 12a, 
which indicates that the aryl ring A is better for the CB2 binding activity. Interestingly, other two 
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compounds of these two series (Compounds 9d and 8a, 6d and 6a) showed similar activity, 
which need further study. 
Table 3.4   Radioligand competition binding affinity and physicochemical properties of 5c-
13c. 
 
Compound R1 MW CLogP Ki (CB2), nM
a Ki (CB1), nM
b SIc 
5c C6H5- 354 4.07 1200 2276 1.9 
6c p-CH3-C6H5- 368 4.56 1000 1883 1.9 
7c p-F-C6H5- 372 4.23 2900 1769 0.6 
8c p-Br-C6H5- 433 4.90 380.8 1305 3.4 
9c p-CF3-C6H5- 422 4.99 1300 1840 1.4 
10c p-C(CH3)3-C6H5- 410 5.78 32.6 648.4 20 
11c p-N(CH3CH2)2-C6H5- 425 5.03 30.7 13350 435 
12c C4H9- 334 4.13 3700 12620 3.4 
13c C5H11- 348 4.55 2000 5858 2.9 
Lead  - 452 4.50 105 836 7.9 
CP 55,940 - - - 0.35 NT - 
SR144528 - - - 2.05 NT - 
SR141716 - - - NT 5.6[90] - 
 
a,b Binding affinities of compounds for CB1 and CB2 receptors were evaluated using a [
3H]-CP 55,940 
radioligand competition binding assay. c SI =selectivity index for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. 
NT: Not tested. CB2 reference compound CP 55,940, SR144528 and CB1 reference compound SR141716. 
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Table 3.5  Radioligand competition binding affinity and physicochemical properties of 5d-
12d. 
 
Compound R1 MW CLogP Ki (CB2), nM
a Ki (CB1), nM
b SIc 
5d C6H5- 328 3.19 1380 10100 7.3 
6d p-CH3O-C6H5- 358 4.09 197.5 1748 8.9 
7d p-CH3-C6H5- 342 3.67 704.1 2356 3.3 
8d p-F-C6H5- 346 3.34 4300 5803 1.3 
9d p-Br-C6H5- 407 4.02 561.2 773.5 1.4 
10d p-C(CH3)3-C6H5- 384 4.89 79.1 281.2 3.6 
11d p-N(CH3CH2)2-C6H5- 399 4.15 16.2 1592 98.2 
12d C4H9- 308 3.25 28700 306.3 0.01 
Lead  - 452 4.50 105 836 7.9 
CP 55,940 - - - 0.35 NT - 
SR144528 - - - 2.05 NT - 
SR141716 - - - NT 5.6[90] - 
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a,b Binding affinities of compounds for CB1 and CB2 receptors were evaluated using a [
3H]-CP 55,940 
radioligand competition binding assay. c SI =selectivity index for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. 
NT: Not tested. CB2 reference compound CP 55,940, SR144528 and CB1 reference compound SR141716. 
3.5   OFF-TARGET EFFECTS PREDICTION  
Then, we use several of our best compounds 11a, 7b, 10c and 11d to study the off-target (either 
bad or good) effects of this series of novel scaffolds. By utilizing high-throughput docking (HT-
docking) and online databases our lab created (http://www.cbligand.org/OP/) 
(http://www.cbligand.org/MM/), we were able to find many osteoporosis or multiple myeloma 
related targets that have a high docking score with our compound (7b). 
Also, we confirm it by looking into the interaction networks of these representative compounds 
and their potential targets (Figure 3.7, Figure 3.8). Many overlapping targets which related to 
osteoporosis or multiple myeloma are shown. (Table 3.6, Table 3.7) 
For example, selective estrogen receptor modulators were reported to have relationship with 
postmenopausal osteoporosis [91] while vitamin D3 receptor was reported to be crucial in the 
balance between bone resorption and bone formation [92]. Similarly, heat shock protein 90 
inhibitor NVP-AUY922 and Aurora Kinase Inhibitor Alisertib (MLN8237) was reported as 
monotherapy or in combination with bortezomib for the treatment of relapsed or refractory 
multiple myeloma [93, 94]. These results not only indicate other potential targets that our 
compounds might have, but also confirm the therapeutic effects of our compound in osteoporosis 
and multiple myeloma. Moreover, the underlying mechanism of treating osteoporosis and 
multiple myeloma using this novel scaffold can be further studied based on these findings. 
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Figure 3.7  Interaction network of representative compounds and their potential targets for OP 
Four large circles with chemical structures represent the three representative molecules we selected with 
best affinity. Each constitute is linked to its predicted targets, represented by nodes.  
Abbreviation: PR, Progesterone receptor; SPARC, Serum secreted protein acidic and rich in cysteine; IL-
1β, Interleukin-1β; SMAD4, Mothers against decapentaplegic homolog 4; PTK2β, Protein-tyrosine kinase 
2β; CYP17A1, Steroid 17-alpha-hydroxylase/17,20 lyase; LTF, Lactotransferrin; HGF, Hepatocyte 
growth factor; IL4, Interleukin-4; HSD1, Corticosteroid 11-beta-dehydrogenase isozyme 1; ALDH, 
Aldehyde dehydrogenase, mitochondrial; SHBG, Sex hormone-binding globulin; MAPK1, Mitogen-
activated protein kinase 1; ESR, Estrogen receptor; CYP19A1, Cytochrome P450 19A1; CYP3A4, 
Cytochrome P450 3A4; CYP1A1, Cytochrome P450 1A1; GSTT1, Glutathione S-transferase theta-1; 
VDR, Vitamin D3 receptor; PTH1R, Parathyroid hormone/parathyroid hormone-related peptide receptor; 
IGF1R, Insulin-like growth factor 1 receptor; IL6, Interleukin-6; NOS3, Nitric oxide synthase, 
endothelial; PAI1, Plasminogen activator inhibitor 1; TRAF6, TNF receptor-associated factor 6; SCFR, 
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Mast/stem cell growth factor receptor Kit; hGH, Somatotropin; QPCT, Glutaminyl-peptide 
cyclotransferase; NQO1, NAD(P)H dehydrogenase [quinone] 1. 
 
 
Figure 3.8  Interaction network of representative compounds and their potential targets for MM 
Four large circles with chemical structures represent the three representative molecules we selected with 
best affinity. Each constitute is linked to its predicted targets, represented by nodes.  
Abbreviation: CDK9, Cyclin-dependent kinase 9; CDK7, Cyclin-dependent kinase 7; MMP-2, 72 kDa 
type IV collagenase; PDGFA, Platelet-derived growth factor subunit A; CASP3, Caspase-3; FGFR1, 
Fibroblast growth factor receptor 1; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA reductase; RRM1, 
Ribonucleoside-diphosphate reductase large subunit; LYN, Tyrosine-protein kinase Lyn; APPBP1, 
NEDD8-activating enzyme E1 regulatory subunit; CDK6, Cyclin-dependent kinase 6; FLT3, receptor-
type tyrosine-protein kinase; CSNK2A2, Casein kinase II subunit alpha; JAK1, tyrosine kinase; HGFR, 
hepatocyte growth factor receptor; AKT1, RAC-alpha serine/threonine-protein kinase; AURKA, Aurora 
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kinase A; HSP90, Heat shock protein 90; MAPK14, Mitogen-activated protein kinase 14; FDPS, 
Dimethylallyltranstransferase; PPARG, Peroxisome proliferator-activated receptor gamma; CDK2, 
Cyclin-dependent kinase 2; PIK3CG, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
gamma isoform; BRAF, serine/threonine-protein kinase B-Raf; PARP, Poly (ADP-ribose) polymerase; 
GR, glucocorticoid receptor; EGFR, epidermal growth factor receptor; TEK, Angiopoietin-1 receptor; c-
SRC, Proto-oncogene tyrosine-protein kinase Src; ABL1, Abelson murine leukemia viral oncogene 
homolog 1; AURKB, Aurora B kinase; VEGFR-2, Kinase insert domain receptor; RXR, retinoid X 
receptor; CFTR, Cystic fibrosis transmembrane conductance regulator; RAC-β, RAC-beta 
serine/threonine-protein kinase; TNF, Tumor necrosis factors; c-kit, Mast/stem cell growth factor receptor; 
CDK4, Cyclin-dependent kinase 4; TXNRD1, Thioredoxin reductase 1. 
 
Table 3.6  HT-docking of compound 7b using chemogenomics database for osteoporosis 
PDB ID PROTEIN 
DOCKING 
SCORE 
1err Estrogen receptor 8.51 
3tkc Vitamin D3 receptor 8.43 
2ojg Mitogen-activated protein kinase 1 8.13 
2c3q Glutathione S-transferase theta-1 7.91 
1xu7 
Corticosteroid 11-beta-
dehydrogenase isozyme 1 
7.68 
4i4h Cytochrome P450 3A4 7.59 
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Table 3.7  HT-docking of compound 7b using chemogenomics database for multiple 
myeloma 
PDB ID PROTEIN 
DOCKING 
SCORE 
2ye7 Heat shock protein HSP 90-alpha 8.93 
3uok Aurora kinase A 8.62 






4.0  CONCLUSION 
In this study, many ligand discovery tools were utilized in order to identify novel CB2 selective 
compounds. High-throughput virtual screening was used to discover the lead compound 
(NCI374672) with novel structure (β-keto sulfones and α, β double bond). Physicochemical 
property predication, molecular docking study and biological validations were then conducted. 
To get more drug-like compounds, various optimization strategies were considered based on the 
docking score, binding mode and the solubility of novel scaffolds. As a result, we designed and 
synthesized 29 analogues using a similar three-step synthetic route, and evaluated their binding 
affinity against two subtypes of cannabinoid receptors CB1 and CB2 as well as their CB1/CB2 
selectivity. Among these new analogues, four compounds showed high CB2 binding affinity (Ki 
< 60 nM) and good selectivity (CB1/CB2 of 20- to 1305 fold). The best compound 7b showed a 
CB2 binding affinity (Ki) equals to 10.9 nM and selectivity index more than 1000 folds. 
Moreover, off-target effects were predicted using HT-docking and chemogenomics databases. 
In summary, these studies are significant for future drug development and this novel series of 
CB2 ligands are promising as potential treatment for osteoporosis and multiple myeloma. 
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5.0  FUTURE PROSPECTIVES 
We have already got several novel potent CB2 selective compounds with Ki value around 10nM. 
In order to get more drug-like CB2 oral drug, further optimizations are needed to improve the 
solubility or bioavailability of our compounds. We will also test the compounds’ efficacy (using 
[35S]GTPγS binding assay) and toxicity (using MTT assay). In vivo assay might also be conducted 
for the best compounds. Additional SAR of this series of compounds will be studied based on 
new bioactivity data. 
Additionally, scaffold hopping and pharmacophore model will be utilized for the design of CB 
ligands with new structure. Based on the results from chemogenomics database for multiple 
myeloma (http://www.cbligand.org/MM/) and chemogenomics database for osteoporosis 
(http://www.cbligand.org/OP), we can also design new chemical entities that can act on other 
targets related to multiple myeloma and osteoporosis. To further confirm our speculations, 
biological validations will also be conducted. 
Moreover, to distinguish CB agonists from antagonists/inverse agonists based on their structures 
are quite difficult. We will build computational methods to predict whether a special structure is 
more likely to make a compound act as an agonist or an inverse agonist before its efficacy is 
actually tested. Dockings and pharmacophore model will also be used to study the correlation 
between functional groups and compounds’ efficacies. This will help us design druggable CB 
ligands which can be used in certain diseases with certain functions and less side effects. 
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To enhance the selectivity of our compounds, we will also look into the design of novel CB2 
allosteric modulators and study their mechanisms in terms of altering the conformation of CB2 
receptor. 
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6.0  EXPERIMENTAL 
6.1   CHEMISTRY 





4-Methoxybenzenesulfonyl chloride (5.25 g, 25.5 mmol) was added in water (145 mL). Na2SO3 
(5.4 g, 43.4 mmol) and NaHCO3 (3.6 g, 43.4 mmol) were added to the solution. The mixture was 
heated under reflux at 100 °C for 24 h. Then an ethanolic solution of 2-bromo-1-phenylethan-1-
one (4.57 g, 22.95 mmol) was added slowly to the mixture. After 24 h, reaction was cooled down 
to room temperature. Diluted HCl was used to neutralize the solution and gave solid product. 
The product was filtered and washed by ethanol to give the desired compound (2.6 g, Yield: 
35.1%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.94-7.97 (m, 2H), 7.80-7.83 (m, 2H), 7.66-7.70 (m, 











HNMR (400 MHz, DMSO-d6) δ 8.05-8.07 (m, 2H), 7.70-7.75 (m, 1H), 7.57-7.60 






HNMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 8Hz, 2H), 7.92 (d, J = 7.2Hz, 2H), 





HNMR (400 MHz, DMSO-d6) δ 8.09-8.11 (m, 1H), 7.96-7.99 (m, 2H), 7.79-7.80 





6.1.2 General synthesis procedure of sulfone derivatives 
(E)-2-((4-Methoxyphenyl)sulfonyl)-1,3-diphenylprop-2-en-1-one (5a) 
 
2-((4-methoxyphenyl) sulfonyl)-1-phenylethan-1-one (290mg, 1mmol) was dissolved by toluene 
(20ml). Benzaldehyde (117mg, 1.1mmol) was then added to the solution. Piperidine (16mg, 
0.2mmol) and acetic acid (30mg, 0.5mmol) were added to the mixture. The reaction system was 
heated at reflux for 24h (115°C-120°C). After the reaction is completed, cool down the system 
and add toluene to dissolve the mixture. Flash column was run afterwards. Desired compound is 
given (180mg, Yield: 47.6%). 
1
HNMR (400 MHz, DMSO-d6) δ 8.11 (s, 1H), 7.76-7.79 (m, 4H), 





HNMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.74-7.80 (m, 3H), 7.63-7.67 (m, 









HNMR (400 MHz, DMSO-d6) δ 8.13 (s, 1H), 7.75-7.78 (m, 4H), 7.62-7.66 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.15-8.16 (m, 2H), 7.76-7.78 (m, 3H), 7.63-7.66 






HNMR (400 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.74-7.8 (m, 4H), 7.61-7.69 (m, 







HNMR (400 MHz, DMSO-d6) δ 8.03 (s, 1H), 7.79-7.82 (m, 2H), 7.73-7.76 (m, 
2H), 7.64-7.66 (m, 1H), 7.47-7.50 (m, 2H), 7.27-7.35 (m, 4H), 7.12-7.14 (m, 2H), 3.33 (s, 3H), 






HNMR (400 MHz, DMSO-d6) δ 7.80-7.84 (m, 3H), 7.71-7.74 (m, 2H), 7.63-7.66 
(m, 1H), 7.46-7.50 (m, 2H), 7.10-7.12 (m, 4H), 6.51-6.53 (d, J = 8.8Hz 2H), 3.85 (s, 3H), 3.29-











HNMR (400 MHz, DMSO-d6) δ 8.05-8.08 (m, 2H), 7.69-7.72 (m, 3H), 7.52-7.57 
(m, 2H), 7.13-7.15 (m, 2H), 6.20-6.23 (m, 1H), 3.86 (s, 3H), 1.97-2.00 (m, 2H), 1.25-1.28 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.06-8.08 (m, 2H), 7.70-7.72 (m, 3H), 7.52-7.56 
(m, 2H), 7.13-7.15 (m, 2H), 6.20-6.23 (m, 1H), 3.82 (s, 3H), 1.99-2.00 (m, 2H), 1.12-1.24 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.19 (s, 1H), 7.86-7.88 (m, 2H), 7.76-7.78 (m, 






HNMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.84-7.87 (m, 2H), 7.71-7.78 (m, 






HNMR (400 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.79-7.83 (m,4H), 7.58-7.70 (m, 
4H), 7.48 (dd, J = 7.6Hz, 2H), 7.13 (d, J = 8.8Hz, 2H), 6.52 (d, J = 9.2Hz, 2H), 3.23-3.31 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.13-8.14 (m, 2H), 7.75-7.78 (m, 3H), 7.61-7.65 






HNMR (400 MHz, DMSO-d6) δ 8.12-8.14 (m, 1H), 8.09 (s, 1H), 7.73-7.78 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H), 8.13-8.15 (m, 1H), 7.74-7.78 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.15-8.16 (m, 2H), 7.76-7.78 (m, 3H), 7.63-7.66 









HNMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 8.17-8.18 (m, 1H), 7.76-7.80 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.12-8.14 (m, 1H), 8.07 (s, 1H), 7.81-7.83 (m, 
2H), 7.72-7.73 (m, 1H), 7.65-7.68 (m, 1H), 7.48-7.52 (m, 2H), 7.31-7.37 (m, 4H), 7.23-7.25 (m, 





HNMR (400 MHz, DMSO-d6) δ 8.05-8.06 (m, 1H), 7.81-7.87 (m, 3H), 7.63-7.66 







HNMR (400 MHz, DMSO-d6) δ 8.08-8.16 (m, 3H), 7.70-7.71 (m, 2H), 7.56-7.58 






HNMR (400 MHz, DMSO-d6) δ 8.08-8.16 (m, 3H), 7.69-7.71 (m, 2H), 7.54-7.58 






HNMR (400 MHz, DMSO-d6) δ 7.94 (s, 1H), 7.87 (d, J = 7.2Hz, 2H), 7.65 (dd, J 
= 7.6Hz, 1H), 7.49 (dd, J = 7.6Hz, 2H), 7.29-7.38 (m, 5H), 3.41 (t, J = 8Hz, 2H), 1.69-1.77 (m, 






HNMR (400 MHz, DMSO-d6) δ 7.89 (d, J = 7.6Hz, 2H), 7.84 (s, 1H), 7.67 (dd, J 
= 7.2Hz, 1H), 7.52 (dd, J = 8Hz, 2H), 7.33 (d, J = 9.2Hz, 2H), 6.88 (d, J = 8.8Hz, 2H), 3.72 (s, 





HNMR (400 MHz, DMSO-d6) δ 7.86-7.89 (m, 3H), 7.64-7.68 (m,1H), 7.50 (dd, J 
= 7.6Hz, 2H), 7.26 (d, J = 8Hz, 2H), 7.13 (d, J = 8Hz, 2H), 3.36-3.40 (m, 2H), 2.23 (s, 3H), 1.68-





HNMR (400 MHz, DMSO-d6) δ 7.95 (s, 1H), 7.87 (d, J = 8Hz, 2H), 7.64-7.69 
(m, 2H), 7.48-7.52 (m, 2H), 7.43-7.46 (m,2H), 7.16-7.20 (m, 2H), 3.40-3.42 (m,2H), 1.69-1.77 






HNMR (400 MHz, DMSO-d6) δ 7.93 (s, 1H), 7.86 (d, J = 8Hz, 2H), 7.62-7.71 
(m,1H), 7.48-7.55 (m, 4H), 7.31 (d, J = 8.4Hz, 2H), 3.42 (t, J = 7.6Hz, 2H), 1.69-1.76 (m, 2H), 





HNMR (400 MHz, DMSO-d6) δ 7.90-7.92 ( m, 2H), 7.84 (s, 1H), 7.66-7.70 (m, 
1H), 7.51-7.55 (m, 2H), 7.30-7.37 (m, 4H), 3.36-3.38 (m, 2H), 1.67-1.75 (m, 2H), 1.39-1.49 (m, 






HNMR (400 MHz, DMSO-d6) δ 7.90-7.92 (m, 2H), 7.65-7.69 (m, 2H), 7.51-7.54 
(m, 2H), 7.13 (d, J=8.8Hz, 2H), 6.53 (d, J = 9.2Hz, 2H), 3.26-3.31 (m, 6H), 1.64-1.72 (m, 2H), 





HNMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 7.6Hz, 2H), 7.77 (dd, J = 7.2Hz, 1H), 
7.63 (dd, J = 7.6Hz, 2H), 7.04 (t, J = 8Hz, 1H), 3.25-3.31 (m, 2H), 1.97-2.03 (m, 2H), 1.61-1.69 



















2-AGE 2-Arachidonyl glyceryl ether 




cAMP Cyclic adenosine monophosphate 
cLogP Calculated logarithm of octanol/water partition coefficient 
CB Cannabinoid 
CB1 Cannabinoid receptor 1 
CB2 Cannabinoid receptor 2 
CHO cells Chinese Hamster Ovary cells 
COMFA Comparative molecular field analysis 
DMSO Dimethyl sulfoxide 
ED50 Median effective dose 
EL Extracellular loops 
ERK Extracellular regulated protein kinases 
EtOH Ethanol 
FDA Food and drug administration 
G protein Guanine nucleotide-binding proteins 
GDP Guanosine diphosphate 
GPCRs G-Protein coupled receptors 
GTP Guanosine triphosphate 
HT-docking High-Throughput docking 
ICL Intracellular loops 
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IL Interleukin 
LC-MS Liquid chromatography–mass spectrometry 
MAPK Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
MET Methanandamide 
MHz Megahertz 
MM Multiple myeloma 
MW Molecular Weight 
NA Noradrenaline 
NADA N-arachidonoyl dopamine 
nM Nanomolar 
NMR Nuclear magnetic resonance 
OP Osteoporosis 
PEA N-palmitoylethanolamine 
PKA Protein Kinase A 
QSAR Quantitative structure activity relationship 
RANKL Receptor activator of nuclear factor kappa-B ligand 
SAR Structure activity relationship 
THC Δ9-Tetrahydrocannabinol 
TLC Thin-layer chromatography 
TM Transmembrane domains 
tPSA Topological polar surface area 
UV Ultra-violet 
VOCCs Voltage operated calcium channels 
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